Drugs / Bacteriophage Cocktail
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07280598 | Dec 2025 → Dec 2026 expected | Klebsiella pneumonia, cystic fibrosis, escherichia coli infection, staphylococcus aureus infection | University of California, San Diego | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacteriophage Cocktail | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07280598 ↗ |
| Action | Deplete | “viruses that infect and lyse specific bacteria” NCT07280598 ↗ |
| Modality | Other / unclassified | “bacteriophage therapy consists of a pathogen-specific cocktail containing four purified, lytic bacteriophages” NCT07280598 ↗ |
| Route | Intravenous | “Phage cocktails are administered IV twice daily at a concentration of 1x10⁹ PFU/mL, following antibiotic infusion.” NCT07280598 ↗ |